Please use this identifier to cite or link to this item: https://repositorio.ufrn.br/jspui/handle/123456789/25416
Title: Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis
Authors: Araújo, Aurigena Antunes
Souza, Graziene Lopes de
Souza, Tatiana Oliveira
Brito, Gerly Anne de Castro
Aragão, Karoline Sabóia
Medeiros, Caroline Addison Xavier de
Lourenço, Yriu
Alves, Maria do Socorro Costa Feitosa
Araújo Jr, Raimundo Fernandes de
Keywords: Experimental periodontal disease;Citocines;Immunohistochemical;Lipid peroxidant;Olmesartan
Issue Date: 19-Jun-2013
Publisher: Springer-Verlag Berlin Heidelberg
Citation: ARAÚJO, Aurigena Antunes de et al. Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn-Schmiedeberg's Archives of Pharmacology, p. 875-84, 2013. Disponível em: <https://link.springer.com/article/10.1007/s00210-013-0886-8>. Acesso em: 14 mar. 2018.
Portuguese Abstract: The objective of this study is to investigate the participation of inflammatory and oxidative stress mediators and the effects on the expression of matrix metalloproteinase (MMP)-2, MMP-9, and receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) pathway in the response to treatment with olmesartan, an angiotensin II type 1 receptor blocker. Male Wistar albino rats were randomly divided into five groups of ten rats each: (1) non-ligature with water, (2) ligature with water, (3) ligature with 1 mg/kg olmesartan, (4) ligature with 6 mg/kg olmesartan, and (5) ligature with 10 mg/kg olmesartan. All groups were treated with olmesartan or the vehicle by gavage daily for 10 days. Following the treatment course, the periodontal tissue of the animals was analyzed by histopathology and immunohistochemistry to determine the expression of cyclooxygenase-2 (COX-2), MMP-2, MMP-9, and members of the RANKL/RANK/OPG pathway and by ELISA and spectroscopic assay to determine the levels of interleukin (IL)-1β, IL-10, tumor necrosis factor (TNF)-α, myeloperoxidase (MPO), malonaldehyde (MDA), and glutathione. The concentrations of MPO and MDA were reduced in the group that received 6 mg/kg olmesartan (p < 0.05). In addition, the group that was treated with 6 mg/kg olmesartan showed a decreased level of IL-1β (p < 0.05), and all doses of olmesartan resulted in decreased levels of TNF-α. Furthermore, treatment with 6 mg/kg olmesartan led to downregulation of the expression of COX-2, MMP-2, MMP-9, RANKL, and RANK and to upregulation of the expression of OPG. These findings suggest that 6 mg/kg olmesartan reduces the inflammatory process and bone loss by downregulating MMPs and RANKL in osteoblasts and by upregulating OPG.
URI: https://repositorio.ufrn.br/jspui/handle/123456789/25416
ISSN: 1432-1912
Appears in Collections:CB - DBF - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
Olmesartan decreases_2013.pdf697,73 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.